Xeris Pharmaceuticals | XERS - Ebitda

Aktienkurs
6.05
Täglich Wechseln
0.10 1.68%
Monatlich
14.15%
Jährlich
40.37%
Q2 Prognose
5.92




Ebitda Veränderung Datum
Celltrion KRW 374.56B 352.67B 2025-09
Cspc Pharmaceutical CNY 2.19B 21.88M 2024-12
Deva Holding AS TRY 882.9M 201.7M 2023-09
Dianthus Therapeutics USD -40.19M 5.36M 2025-09
Divis Laboratories Ltd INR 8.9B 20M 2025-12
Eli Lilly USD 7.88B 378.1M 2025-09
Kangmei Pharma CNY 17.3M 20.56M 2025-06
Knight Therapeutics CAD 24.45M 3.46M 2025-12
Laboratorios Farma EUR 34.94M 102.95M 2025-06
Malin Corporation EUR -1.1M 200K 2024-12
Medical Developments International AUD 1.78M 3.78M 2024-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Neuren Pharmaceuticals AUD 11.14M 165.56M 2025-12
Organigram Holdings CAD 5.26M 884K 2025-12
Pacira USD 38.71M 10.65M 2025-12
Perrigo USD 258.8M 37.3M 2025-09
Pharma Mar EUR 44.96M 46.94M 2025-12
Qiagen NV USD 249.69M 56.53M 2025-12
Sartorius EUR 267.3M 10.1M 2026-03
Sino Biopharmaceutical CNY 2.59B 1.57B 2024-12
Supernus Pharmaceuticals USD 48.5M 6.6M 2025-12
Tilray USD 8.36M 1.82M 2025-09
Zealand Pharma A/S -727.47M 285.54M 2025-12
Zhangzhou Pientzehuang Pharmaceutical CNY 531.61M 658.23M 2025-06